This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
How, G., Tan, L. & Lim, L. Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction – is it truly a benign disease?. Leukemia 12, 1166–1167 (1998). https://doi.org/10.1038/sj.leu.2401055
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401055
This article is cited by
-
Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report
BMC Cancer (2018)
-
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts
Leukemia (2004)
-
BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations
Oncogene (2002)
-
The e19a2 BCR/ABL fusion transcript with additional chromosomal aberrations on a new case of chronic myeloid leukemia (CML) of mild type
Leukemia (2001)
-
Molecular Biology of Chronic Myeloid Leukemia
International Journal of Hematology (2001)